上气道刺激治疗阻塞性睡眠呼吸暂停的5年结局
这项多中心前瞻性队列研究纳入126例经单侧舌下神经植入上气道刺激(UAS)的中重度阻塞性睡眠呼吸暂停(OSA)患者,97例完成方案,71例同意进行多导睡眠监测。5年随访显示嗜睡和生活质量改善,呼吸暂停低通气指数(AHI)应答率为75%,严重设备相关事件发生率为6%。
要点
- UAS治疗5年可改善嗜睡、生活质量和呼吸结局。
- AHI应答率75%(AHI<20次/小时且降低>50%),末次观测结转分析为63%。
- 严重设备相关事件发生率为6%,均与导线或设备调整相关。
核心结论
- UAS治疗5年可观察到嗜睡、生活质量和呼吸结局的改善,严重不良事件不常见。
- UAS是一种非解剖性手术治疗,对鼻持续气道正压通气失败的中重度OSA患者具有长期获益。
研究设计与样本
- 多中心前瞻性队列研究,纳入126例患者,97例完成方案,71例同意自愿多导睡眠监测。
- 入组条件为持续气道正压通气失败的中重度OSA、体重指数<32 kg/m2且药物诱导睡眠内镜无不利塌陷。
主要发现
- 嗜睡(Epworth嗜睡量表)和生活质量改善,评分正常化比例分别从33%升至78%和从15%升至67%。
- AHI应答率(AHI<20次/小时且降低>50%)为75%(n=71),末次观测结转分析5年应答率为63%。
- 严重设备相关事件发生率为6%,均与导线或设备调整相关。
关键数值与推荐
- AHI应答定义为AHI<20次/小时且降低>50%。
- 完成方案与未完成方案的患者在基线AHI、氧减指数和功能结局睡眠问卷评分上存在差异,其他人口学或治疗反应指标无差异。
临床怎么用
- 对于鼻持续气道正压通气失败的中重度OSA患者,UAS可作为非解剖性手术选择,具有5年长期获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective To present 5-year outcomes from a prospective cohort of patients with obstructive sleep apnea (OSA) who were treated with upper airway stimulation (UAS) via a unilateral hypoglossal nerve implant. Study Design A multicenter prospective cohort study. Setting Industry-supported multicenter academic and clinical trial. Methods From a cohort of 126 patients, 97 completed protocol, and 71 consented to a voluntary polysomnogram. Those having continuous positive airway pressure failure with moderate to severe OSA, body mass index <32 kg/m2, and no unfavorable collapse on drug-induced sleep endoscopy were enrolled in a phase 3 trial. Prospective outcomes included apnea-hypopnea index (AHI), oxygen desaturation index, and adverse events, as well as measures of sleepiness, quality of life, and snoring. Results Patients who did and did not complete the protocol differed in baseline AHI, oxygen desaturation index, and Functional Outcomes of Sleep Questionnaire scores but not in any other demographics or treatment response measures. Improvement in sleepiness (Epworth Sleepiness Scale) and quality of life was observed, with normalization of scores increasing from 33% to 78% and 15% to 67%, respectively. AHI response rate (AHI <20 events per hour and >50% reduction) was 75% (n = 71). When a last observation carried forward analysis was applied, the responder rate was 63% at 5 years. Serious device-related events all related to lead/device adjustments were reported in 6% of patients. Conclusions Improvements in sleepiness, quality of life, and respiratory outcomes are observed with 5 years of UAS. Serious adverse events are uncommon. UAS is a nonanatomic surgical treatment with long-term benefit for individuals with moderate to severe OSA who have failed nasal continuous positive airway pressure.
引用
- Woodson BT, Strohl KP, Soose RJ, et al. Upper Airway Stimulation for Obstructive Sleep Apnea: 5-Year Outcomes. Otolaryngol Head Neck Surg. 2018. PMID: 29582703. doi:10.1177/0194599818762383
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。